At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 28 enrolled
Drug / intervention
MK-1167 +2 moredrug
Likely dose
MK-1167 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MK-1167 Administered to Patients With Alzheimer's Disease Receiving Stable Donepezil Treatment
In Brief
A Phase 1 clinical trial evaluating MK-1167, Donepezil, and 1 other intervention for Alzheimer's Disease. Completed, enrolled 28 participants across 3 sites.
Detailed Summary
The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20252026
First PostedFeb 2024
Enrollment StartMar 2024
Primary CompletionSep 2024
TodayJul 2026
First PostedFeb 29, 2024
Enrollment StartMar 28, 2024
Primary CompletionSep 23, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.3 years ago
Interventions
MK-1167drug
1 mg and 5 mg oral capsules
Donepezildrug
10 mg oral tablets
Placebodrug
MK-1167 matching placebo administered oral capsules